Registry of Celution Device for the Processing of Adipose Derived Regenerative Cells (ADRCs) to Treat Osteoarthritis
Launched by CYTORI THERAPEUTICS · Apr 12, 2016
Trial Information
Current as of May 30, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males or females \> 18 years of age
- • Diagnosis of osteoarthritis in one or both knees with Kellgren Lawrence grade ≥ 2 at x-ray evaluation or MRI findings of degenerative changes
- • Pain with or without swelling in the affected area for \>4 months
- Exclusion Criteria:
- • Know spine or disc disease or symptomatic nerve impingement contributing to pain in the affected limb
- • History of documented nerve damage in the affected limb
- • Pregnant or lactating status. Pregnancy as determined by a positive pregnancy test prior to procedure.
About Cytori Therapeutics
Cytori Therapeutics is a pioneering biotechnology company focused on the development and commercialization of innovative cell-based therapies aimed at addressing unmet medical needs in regenerative medicine. With a commitment to leveraging the potential of adipose-derived stem and regenerative cells, Cytori is advancing treatments for conditions such as cardiovascular disease, orthopedic injuries, and soft tissue reconstruction. The company is dedicated to rigorous clinical research and collaboration with healthcare professionals to translate scientific advancements into effective therapeutic solutions, ultimately improving patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Steven Kesten
Study Chair
Cytori Therapeutics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials